Folgen
Mary V. Relling
Mary V. Relling
Bestätigte E-Mail-Adresse bei stjude.org
Titel
Zitiert von
Zitiert von
Jahr
Pharmacogenomics: translating functional genomics into rational therapeutics
WE Evans, MV Relling
science 286 (5439), 487-491, 1999
33611999
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ...
Nature genetics 27 (4), 383-391, 2001
27402001
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
EJ Yeoh, ME Ross, SA Shurtleff, WK Williams, D Patel, R Mahfouz, ...
Cancer cell 1 (2), 133-143, 2002
24192002
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
CG Mullighan, S Goorha, I Radtke, CB Miller, E Coustan-Smith, JD Dalton, ...
Nature 446 (7137), 758-764, 2007
21742007
Acute lymphoblastic leukemia
CH Pui, MV Relling, JR Downing
New England Journal of Medicine 350 (15), 1535-1548, 2004
20142004
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
CG Mullighan, X Su, J Zhang, I Radtke, LAA Phillips, CB Miller, J Ma, ...
New England Journal of Medicine 360 (5), 470-480, 2009
17082009
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ...
New England journal of medicine 371 (11), 1005-1015, 2014
15412014
Treating childhood acute lymphoblastic leukemia without cranial irradiation
CH Pui, D Campana, D Pei, WP Bowman, JT Sandlund, SC Kaste, ...
New England Journal of Medicine 360 (26), 2730-2741, 2009
14542009
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, ...
Nature 453 (7191), 110-114, 2008
12302008
CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network
MV Relling, TE Klein
Clinical Pharmacology & Therapeutics 89 (3), 464-467, 2011
11602011
Childhood acute lymphoblastic leukemia: progress through collaboration
CH Pui, JJ Yang, SP Hunger, R Pieters, M Schrappe, A Biondi, A Vora, ...
Journal of Clinical Oncology 33 (27), 2938-2948, 2015
10272015
Moving towards individualized medicine with pharmacogenomics
WE Evans, MV Relling
Nature 429 (6990), 464-468, 2004
10032004
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance
CR Yates, EY Krynetski, T Loennechen, MY Fessing, HL Tai, CH Pui, ...
Annals of internal medicine 126 (8), 608-614, 1997
9891997
Pharmacogenomics in the clinic
MV Relling, WE Evans
Nature 526 (7573), 343-350, 2015
9122015
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing
MV Relling, EE Gardner, WJ Sandborn, K Schmiegelow, CH Pui, SW Yee, ...
Clinical Pharmacology & Therapeutics 89 (3), 387-391, 2011
8942011
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Y Liu, J Easton, Y Shao, J Maciaszek, Z Wang, MR Wilkinson, ...
Nature genetics 49 (8), 1211-1218, 2017
8902017
Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus
MV Relling, ML Hancock, GK Rivera, JT Sandlund, RC Ribeiro, ...
Journal of the National Cancer Institute 91 (23), 2001-2008, 1999
8701999
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
CH Pui, CG Mullighan, WE Evans, MV Relling
Blood, The Journal of the American Society of Hematology 120 (6), 1165-1174, 2012
7762012
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment
A Holleman, MH Cheok, ML den Boer, W Yang, AJP Veerman, ...
New England Journal of Medicine 351 (6), 533-542, 2004
7362004
Implementing genomic medicine in the clinic: the future is here
TA Manolio, RL Chisholm, B Ozenberger, DM Roden, MS Williams, ...
Genetics in Medicine 15 (4), 258-267, 2013
6382013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20